Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tumor-immunology jargon, trial readouts, and frequent capital raises make Purple Biotech鈥檚 SEC disclosures dense. A single Purple Biotech annual report 10-K simplified still runs hundreds of pages, while each Purple Biotech 8-K material events explained can shift sentiment overnight. If you鈥檝e ever asked 鈥淲here can I find Purple Biotech quarterly earnings report 10-Q filing?鈥� or searched for 鈥�Purple Biotech insider trading Form 4 transactions,鈥� you know the challenge.
Stock Titan鈥檚 AI turns that challenge into clarity. Our platform streams every Purple Biotech SEC filings explained simply the moment they hit EDGAR and delivers AI-powered summaries that translate oncology science and financial footnotes into plain English. Whether you need Purple Biotech Form 4 insider transactions real-time, a Purple Biotech proxy statement executive compensation breakdown, or a quick Purple Biotech earnings report filing analysis, the information appears in seconds. Interactive dashboards connect text, tables, and exhibits, helping you understand Purple Biotech SEC documents with AI rather than hours of scrolling.
Because PPBT is a clinical-stage biotech, filings often reveal cash runway, trial milestones, collaboration terms, and Purple Biotech executive stock transactions Form 4鈥攄etails that drive valuation long before revenue. Investors track 10-Q R&D spend to gauge burn, monitor 8-K headlines for trial updates, and watch for insider buys that may signal confidence. With comprehensive coverage, real-time alerts, and expert commentary, Stock Titan equips you to follow every Purple Biotech disclosure and make informed decisions faster.
Purple Biotech Ltd. (PPBT) filed a Form 6-K on 23 June 2025. The sole purpose of the submission is to furnish a press release titled 鈥淧urple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.鈥� The press release is included as Exhibit 99.1.
The filing contains no financial statements, earnings figures, or transactional details. It merely places the press release鈥攁nd all statements therein鈥攊nto the U.S. public record and incorporates the document by reference into numerous outstanding registration statements (Forms S-8, F-1 and F-3) dating from 2016 through 2024. The Company also confirms that Chief Executive Officer Gil Efron signed the submission on behalf of the registrant.
Because the actual press release text is not included, investors only learn that Purple Biotech believes its CAPTN-3 tri-specific antibody platform demonstrates 鈥渟ignificant advantages鈥� and that these data were highlighted at the European Association for Cancer Research (EACR) 2025 Annual Congress. No quantitative efficacy results, clinical-stage milestones, or development timelines are provided in this 6-K.
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
